Trial Profile

Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B-ALL

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD19 anti-CD 22 chimeric antigen receptor T cell therapy-Chongqing Precision Biotech (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Chongqing Precision Biotech Co., Ltd

Most Recent Events

25 Feb 2025 Planned End Date changed from 1 Jul 2024 to 1 Jul 2027.
25 Feb 2025 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2026.
16 Apr 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com